Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington's disease

Bronwen Martin, Erin Golden, Olga D. Carlson, Paul Pistell, Jie Zhou, Wook Kim, Brittany P. Frank, Sam Thomas, Wayne A. Chadwick, Nigel H. Greig, Gillian P. Bates, Kirupa Sathasivam, Michel Bernier, Stuart Maudsley, Mark P. Mattson, Josephine M. Egan

Research output: Contribution to journalArticle

Abstract

OBJECTIVE-The aim of this study was to find an effective treatment for the genetic form of diabetes that is present in some Huntington's disease patients and in Huntington's disease mouse models. Huntington's disease is a neurodegenerative disorder caused by a polyglutamine expansion within the huntingtin protein. Huntington's disease patients exhibit neuronal dysfunction/degeneration, chorea, and progressive weight loss. Additionally, they suffer from abnormalities in energy metabolism affecting both the brain and periphery. Similarly to Huntington's disease patients, mice expressing the mutated human huntingtin protein also exhibit neurodegenerative changes, motor dysfunction, perturbed energy metabolism, and elevated blood glucose levels. RESEARCH DESIGN AND METHODS-Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit. Blood glucose and insulin levels and various appetite hormone concentrations were measured during the study. Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain. RESULTS-Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease. The treatment also improved motor function and extended the survival time of the Huntington's disease mice. These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells. CONCLUSIONS-Targeting both peripheral and neuronal deficits, Ex-4 is an attractive agent for therapeutic intervention in Huntington's disease patients suffering from diabetes.

Original languageEnglish (US)
Pages (from-to)318-328
Number of pages11
JournalDiabetes
Volume58
Issue number2
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Huntington Disease
Pathology
Survival
Brain
Energy Metabolism
Blood Glucose
Pancreas
exenatide
Chorea
Appetite
Mutant Proteins
Therapeutics
Islets of Langerhans
Hypoglycemic Agents
Neurodegenerative Diseases
Weight Loss
Research Design
Hormones
Insulin
Glucose

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington's disease. / Martin, Bronwen; Golden, Erin; Carlson, Olga D.; Pistell, Paul; Zhou, Jie; Kim, Wook; Frank, Brittany P.; Thomas, Sam; Chadwick, Wayne A.; Greig, Nigel H.; Bates, Gillian P.; Sathasivam, Kirupa; Bernier, Michel; Maudsley, Stuart; Mattson, Mark P.; Egan, Josephine M.

In: Diabetes, Vol. 58, No. 2, 02.2009, p. 318-328.

Research output: Contribution to journalArticle

Martin, B, Golden, E, Carlson, OD, Pistell, P, Zhou, J, Kim, W, Frank, BP, Thomas, S, Chadwick, WA, Greig, NH, Bates, GP, Sathasivam, K, Bernier, M, Maudsley, S, Mattson, MP & Egan, JM 2009, 'Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington's disease', Diabetes, vol. 58, no. 2, pp. 318-328. https://doi.org/10.2337/db08-0799
Martin, Bronwen ; Golden, Erin ; Carlson, Olga D. ; Pistell, Paul ; Zhou, Jie ; Kim, Wook ; Frank, Brittany P. ; Thomas, Sam ; Chadwick, Wayne A. ; Greig, Nigel H. ; Bates, Gillian P. ; Sathasivam, Kirupa ; Bernier, Michel ; Maudsley, Stuart ; Mattson, Mark P. ; Egan, Josephine M. / Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington's disease. In: Diabetes. 2009 ; Vol. 58, No. 2. pp. 318-328.
@article{144b7ee80bdb4dfeb043ef1470daf214,
title = "Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington's disease",
abstract = "OBJECTIVE-The aim of this study was to find an effective treatment for the genetic form of diabetes that is present in some Huntington's disease patients and in Huntington's disease mouse models. Huntington's disease is a neurodegenerative disorder caused by a polyglutamine expansion within the huntingtin protein. Huntington's disease patients exhibit neuronal dysfunction/degeneration, chorea, and progressive weight loss. Additionally, they suffer from abnormalities in energy metabolism affecting both the brain and periphery. Similarly to Huntington's disease patients, mice expressing the mutated human huntingtin protein also exhibit neurodegenerative changes, motor dysfunction, perturbed energy metabolism, and elevated blood glucose levels. RESEARCH DESIGN AND METHODS-Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit. Blood glucose and insulin levels and various appetite hormone concentrations were measured during the study. Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain. RESULTS-Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease. The treatment also improved motor function and extended the survival time of the Huntington's disease mice. These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells. CONCLUSIONS-Targeting both peripheral and neuronal deficits, Ex-4 is an attractive agent for therapeutic intervention in Huntington's disease patients suffering from diabetes.",
author = "Bronwen Martin and Erin Golden and Carlson, {Olga D.} and Paul Pistell and Jie Zhou and Wook Kim and Frank, {Brittany P.} and Sam Thomas and Chadwick, {Wayne A.} and Greig, {Nigel H.} and Bates, {Gillian P.} and Kirupa Sathasivam and Michel Bernier and Stuart Maudsley and Mattson, {Mark P.} and Egan, {Josephine M.}",
year = "2009",
month = "2",
doi = "10.2337/db08-0799",
language = "English (US)",
volume = "58",
pages = "318--328",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "2",

}

TY - JOUR

T1 - Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington's disease

AU - Martin, Bronwen

AU - Golden, Erin

AU - Carlson, Olga D.

AU - Pistell, Paul

AU - Zhou, Jie

AU - Kim, Wook

AU - Frank, Brittany P.

AU - Thomas, Sam

AU - Chadwick, Wayne A.

AU - Greig, Nigel H.

AU - Bates, Gillian P.

AU - Sathasivam, Kirupa

AU - Bernier, Michel

AU - Maudsley, Stuart

AU - Mattson, Mark P.

AU - Egan, Josephine M.

PY - 2009/2

Y1 - 2009/2

N2 - OBJECTIVE-The aim of this study was to find an effective treatment for the genetic form of diabetes that is present in some Huntington's disease patients and in Huntington's disease mouse models. Huntington's disease is a neurodegenerative disorder caused by a polyglutamine expansion within the huntingtin protein. Huntington's disease patients exhibit neuronal dysfunction/degeneration, chorea, and progressive weight loss. Additionally, they suffer from abnormalities in energy metabolism affecting both the brain and periphery. Similarly to Huntington's disease patients, mice expressing the mutated human huntingtin protein also exhibit neurodegenerative changes, motor dysfunction, perturbed energy metabolism, and elevated blood glucose levels. RESEARCH DESIGN AND METHODS-Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit. Blood glucose and insulin levels and various appetite hormone concentrations were measured during the study. Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain. RESULTS-Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease. The treatment also improved motor function and extended the survival time of the Huntington's disease mice. These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells. CONCLUSIONS-Targeting both peripheral and neuronal deficits, Ex-4 is an attractive agent for therapeutic intervention in Huntington's disease patients suffering from diabetes.

AB - OBJECTIVE-The aim of this study was to find an effective treatment for the genetic form of diabetes that is present in some Huntington's disease patients and in Huntington's disease mouse models. Huntington's disease is a neurodegenerative disorder caused by a polyglutamine expansion within the huntingtin protein. Huntington's disease patients exhibit neuronal dysfunction/degeneration, chorea, and progressive weight loss. Additionally, they suffer from abnormalities in energy metabolism affecting both the brain and periphery. Similarly to Huntington's disease patients, mice expressing the mutated human huntingtin protein also exhibit neurodegenerative changes, motor dysfunction, perturbed energy metabolism, and elevated blood glucose levels. RESEARCH DESIGN AND METHODS-Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit. Blood glucose and insulin levels and various appetite hormone concentrations were measured during the study. Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain. RESULTS-Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease. The treatment also improved motor function and extended the survival time of the Huntington's disease mice. These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells. CONCLUSIONS-Targeting both peripheral and neuronal deficits, Ex-4 is an attractive agent for therapeutic intervention in Huntington's disease patients suffering from diabetes.

UR - http://www.scopus.com/inward/record.url?scp=63249091158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249091158&partnerID=8YFLogxK

U2 - 10.2337/db08-0799

DO - 10.2337/db08-0799

M3 - Article

C2 - 18984744

AN - SCOPUS:63249091158

VL - 58

SP - 318

EP - 328

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -